Combining new and old drugs improves survival for soft-tissu
Adding a novel monoclonal antibody therapy to traditional chemotherapy increased median survival by nearly a year in patients with advanced sarcoma, a lethal soft-tissue cancer. Findings from a multi-center clinical trial of the combination therapy, led by researchers at Columbia University Medical Center and NewYork-Presbyterian, represent the first appreciable improvement in sarcoma outcomes in decades.

Read More:
http://medicalxpress.com/news/2016-07-combining-drugs-survival-soft-tissue-cancer.html
Like
Comment
Share